Dr. Michael J. Hafran, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 30
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
MI license 4301505631 · WI license 49922
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 30
- Services billed
- 146
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Device supply with scheduled recording and transmission for remote monitoring of musculoskeletal system, per 30 days | 41,709 | 7,334 |
| Remote therapeutic monitoring treatment management services by physician or other qualified health care professional, first 20 minutes per calendar month | 39,241 | 7,165 |
| Remote therapeutic monitoring treatment management services by physician or other qualified health care professional, each additional 20 minutes per calendar month | 5,032 | 3,354 |
| Set-up and patient education for remote monitoring of therapy | 3,437 | 3,435 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 417 | 52 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 249 | 41 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 245 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 33 payments worth $3,093 in total to this clinician.
| Eli Lilly and Company | $1,462 |
|---|---|
| Merck Sharp & Dohme LLC | $1,441 |
| AstraZeneca UK Limited | $190 |
| Travel and Lodging | $2,608 |
|---|---|
| Food and Beverage | $449 |
| Education | $36.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $488 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $249 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $249 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $249 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $238 |
| Merck Sharp & Dohme LLC Sep 24, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $233 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $218 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $197 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $126 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $98.00 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 24, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $233 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $488 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $238 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $126 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $97.70 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $249 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $249 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $249 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $218 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $197 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $98.00 |
| Eli Lilly and Company Apr 16, 2025 | Education in-kind | $36.00 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $32.37 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $17.43 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $17.43 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $16.97 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $15.30 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $14.94 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $14.94 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $11.99 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $7.65 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $4.99 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $4.99 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $4.99 |
| Eli Lilly and Company Apr 16, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $2.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 6 companies. The companies reported $2,666,979 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly and Company · Active, not recruiting · NCT06643728 - A master protocol to investigate the efficacy and safety of orforglipron once daily in participants with hypertension and obesity or overweight: randomized, double-blind, placebo-controlled trials (attain-hypertension…
Eli Lilly and Company - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight…
AstraZeneca UK Limited - A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
Novartis Pharmaceuticals Corporation - A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company · Withdrawn · NCT06901349 - A phase 3, 24-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.